GlassScriptPhysician profile
Matthew B Stevens
NPI 1245201086
$15,129.95
in general payments reported to CMS, 2019-2025
50 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $2,074 · 2021: $2,840 · 2022: $2,630 · 2023: $2,200 · 2024: $2,084 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,832.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,752.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,542.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,527.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,510.75 | 2019-2025 | Airsupra, Farxiga, Andexxa |
| Abbvie INC. | $1,296.22 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $979.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $898.82 | 2019-2025 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $820.42 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $794.08 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $516.96 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $393.38 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $358.54 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $285.29 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $268.38 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.08 | 2020-2025 | Xifaxan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.